Drug intelligence / Profile preview

FT538 + elotuzumab

Development stage: Unknown
Lead developer: Fate Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

FT538 + elotuzumab is an investigational combination therapy composed of FT538, a multiplex-engineered, allogeneic natural killer (NK) cell therapy derived from a clonal induced pluripotent stem cell (iPSC) line, and elotuzumab, a SLAMF7-directed monoclonal antibody approved for multiple myeloma. FT538 is engineered with three modifications: a high‑affinity, non-cleavable CD16 Fc receptor for enhanced antibody-dependent cellular cytotoxicity (ADCC), an interleukin-15/IL-15 receptor fusion for cytokine-autonomous NK cell persistence, and a CD38 knockout to confer resistance to fratricide induced by anti-CD38 monoclonal antibodies. In combination, elotuzumab mediates targeting and opsonization of SLAMF7-expressing multiple myeloma cells, while FT538 provides cytotoxic function and persistence. The combination is being evaluated for relapsed/refractory multiple myeloma in early-phase clinical studies[1][3][5][9].

Other names: elotuzumab

Targets

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)SLAMF7 (Signaling lymphocytic activation molecule family member 7)

Beyond the preview

Go deeper on FT538 + elotuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT538 + elotuzumab.

Explore the full profile